← Back to Home

Antibody targeting both EGFR and MET receives FDA accelerated approval for certain head and neck cancers

Some patients whose head and neck cancer has progressed after chemotherapy and immunotherapy now have an additional subcutaneous treatment option. Rybrevant Faspro produced a 42% tumor response rate in a study of 102 patients, but whether it extends survival remains to be determined in a confirmatory trial.

By SURL BioNews

When head and neck cancer continues to progress after chemotherapy and immunotherapy, further treatment options are often limited. On November 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro, giving some adults with recurrent or metastatic head and neck squamous cell carcinoma an additional antibody therapy that targets two molecular targets simultaneously. However, the approval was based on tumor shrinkage and duration of response; these findings do not yet establish that patients live longer.

The approval has clearly defined limits: patients must have received platinum-based chemotherapy and an anti-PD-(L)1 antibody, with disease progression during or after treatment, to receive this drug as monotherapy. Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma is excluded from the indication. This development therefore cannot be broadly applied to all patients with advanced head and neck cancer.

Rybrevant Faspro is a co-formulation of amivantamab and hyaluronidase-lpuj. Amivantamab is a bispecific antibody that recognizes both epidermal growth factor receptor (EGFR) and MET, targeting two signaling pathways involved in tumor growth. According to Johnson & Johnson’s announcement, this is the drug’s first indication outside lung cancer and the first approved dual-targeted therapy in this head and neck cancer treatment setting.

OrigAMI-4, which supported the approval, is a multicenter, open-label Phase 1b/2 study. The primary efficacy population evaluated by the FDA included 102 patients. By blinded independent central review, the overall response rate was 42%, with a 95% confidence interval of 32% to 52%; in other words, tumor shrinkage met the prespecified criteria in approximately four in ten patients. Among those who responded, 56% had responses lasting at least six months. The denominator for this percentage was not the entire study population.

The method of administration also differs. Johnson & Johnson said the formulation can be administered by subcutaneous injection in approximately five minutes. Halozyme confirmed that the product uses its ENHANZE technology, which employs recombinant human hyaluronidase PH20 to facilitate subcutaneous drug delivery. This describes the time needed for the injection, not the entire visit, and does not directly imply better efficacy or lower risk.

Safety remains an important part of treatment decisions. Johnson & Johnson’s announcement stated that serious adverse reactions occurred in 39% of patients in the study, and fatal adverse reactions in 6%. Common reactions included rash, fatigue, nail toxicity, stomatitis, and edema. The warnings listed by the FDA also cover hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, skin reactions, ocular toxicity, and embryo-fetal toxicity. The short injection time does not eliminate these risks.

Accelerated approval allows a drug to enter clinical use based on earlier measures of efficacy, while leaving evidence gaps that must be addressed. The treatment arm supporting this approval had no randomized control group, so the 42% response rate alone cannot establish that the drug is superior to other therapies or improves survival and quality of life. Johnson & Johnson said continued approval may depend on verification of clinical benefit in the ongoing Phase 3 OrigAMI-5 confirmatory trial. That study is being conducted in the first-line treatment setting and will provide the next level of evidence for this dual-targeted strategy.

References

  1. Stock Titan
  2. U.S. Food and Drug Administration
  3. Johnson & Johnson
  4. Halozyme Therapeutics